Navigation Links
Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
Date:5/15/2008

LAUSANNE, Switzerland, May 15 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced the signature of a license agreement with its long-term European pharmaceutical partner, for the marketing of Salvacyl(R)/Moapar(R) 3-month formulation, a gonadotropin releasing hormone (GnRH) agonist analogue, effective in the treatment of severe sexual deviations in adult men by inducing and maintaining a reversible reduction of testosterone to castrate serum levels. Debiopharm has developed and received marketing authorisations for Salvacyl / Moapar in nine major European countries, including France, Germany, UK, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland.

"There is a genuine unmet medical and social need for the treatment of sexual deviations. Not many pharma companies are willing or courageous enough to provide this type of treatment but we feel that we have a responsibility to help doctors and patients with the tools they need, even if it is difficult or controversial," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.

About Salvacyl(R)/Moapar(R)

In the treatment of sexual deviations in men, administration of Salvacyl(R)/Moapar(R) every 3 months is an advantage over daily oral forms or intra-muscular weekly injections required with antiandrogens such as cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA) and there are fewer side effects.

Two studies have shown that regular injections of the active ingredient, triptorelin, over a period of eight months to seven years in male patients with sexual deviations demonstrated a good efficacy and safety profile. Triptorelin produced reversible serum castrate testosterone levels (defined as less than or equal to 1.735 nmol/L) in all patients, and concurrently with the decrease in testosterone levels, triptorelin treatment reduced deviant sexual behaviours in 35/36 patients with severe sexual deviations.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contacts

Kim Bill

VP, Corporate Development

Tel.: +41(0)21-321-01-11

Fax: +41(0)21-321-01-69

kbill@debiopharm.com

Additional Media Contacts

In London

Maitland

Brian Hudspith

Tel: +44(0)20-7379-5151

bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Debiopharm and EPFL Establish an Oncology Chair
2. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
3. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
4. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
5. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
6. Quintiles Signs Agreement to Acquire Eidetics
7. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
8. Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)
9. Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
10. DelSite Signs Technology Evaluation Agreement With Global Pharmaceutical Company for GelSite(R) Polymer
11. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... ... 2017 , ... CTNext , Connecticut’s go-to resource for entrepreneurial support, today ... at Chelsea Piers in Stamford. , Nine finalists, all of whom are Connecticut-based companies ... opportunity to secure $10,000 awards to help support business growth. The winners included:, ...
(Date:6/15/2017)... ... 2017 , ... The newest exhibition at the University City ... and interdisciplinary collaboration. Feature Creep, a solo exhibition by Maximillian Lawrence, opens on ... held at EKG, located at 3600 Market Street in Philadelphia, on Thursday, June ...
(Date:6/15/2017)... Oxford, Conn. (PRWEB) , ... June 15, 2017 ... ... worldwide, has published a new guide on how to assemble a lab workstation. ... easy-to-follow terminology. Workstation components include Adam’s Nimbus or Eclipse balance, AVT anti-vibration table, ...
(Date:6/14/2017)... ... June 14, 2017 , ... Graphite Metallizing Corporation, the ... has appointed Andrew Ondish as Territory Sales Manager for New Jersey, Eastern Pennsylvania, ... Petroleum Engineering from Colorado School of Mines. With nearly thirty years of experience ...
Breaking Biology Technology:
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):